Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database

Maria Teresa Voso, Marianna Criscuolo, Giuseppe Leone, Susanna Fenu, Roberto Latagliata, Francesco Buccisano, Alfonso Piciocchi, Maria Antonietta Aloe-Spiriti, Massimo Breccia, Alessandro Andriani, Stefano Mancini, Pasquale Niscola, Virginia Naso, Carolina Nobile, Anna Lina Piccioni, Mariella D’Andrea, Ada D’Addosio, Adriano Venditti

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

97 Citazioni (Scopus)

Abstract

PURPOSE: The definition of disease-specific prognostic scores plays a fundamental role in the treatment decision-making process in myelodysplastic syndrome (MDS), a group of myeloid disorders characterized by a heterogeneous clinical behavior. PATIENTS AND METHODS: We applied the recently published Revised International Prognostic Scoring System (IPSS-R) to 380 patients with MDS, registered in an Italian regional database, recruiting patients from the city of Rome (Gruppo Romano Mielodisplasie). Patients were selected based on the availability of IPSS-R prognostic factors, including complete peripheral-blood and bone marrow counts, informative cytogenetics, and follow-up data. RESULTS: We validated the IPSS-R score as a significant predictor of overall survival (OS) and leukemia-free survival (LFS) in MDS (P < .001 for both). When comparing the prognostic value of the International Prognostic Scoring System (IPSS), WHO Prognostic Scoring System (WPSS), and IPSS-R, using the Cox regression model and the likelihood ratio test, a significantly higher predictive power for LFS and OS became evident for the IPSS-R, compared with the IPSS and WPSS (P < .001 for both). The multivariate analysis, including IPSS, WPSS, age, lactate dehydrogenase, ferritin concentration, Eastern Cooperative Oncology Group performance status, transfusion dependency, and type of therapy, confirmed the significant prognostic value of IPSS-R subgroups for LFS and OS. Treatment with lenalidomide and erythropoiesis-stimulating agents was shown to be an independent predictor of survival in the multivariate analysis. CONCLUSION: Our data confirm that the IPSS-R is an excellent prognostic tool in MDS in the era of disease-modifying treatments. The early recognition of patients at high risk of progression to aggressive disease may optimize treatment timing in MDS.
Lingua originaleEnglish
pagine (da-a)2671-2677
Numero di pagine7
RivistaJournal of Clinical Oncology
Volume31
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • IPSS-R
  • MDS

Fingerprint

Entra nei temi di ricerca di 'Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database'. Insieme formano una fingerprint unica.

Cita questo